[cancerpage is a service of Alere]

Today is Thursday, February 09, 2012


When this edition of Words To Live By was originally published, the links below opened active web pages.
Because many web sites discard or move content after a period of time, some links included here may no longer work.


New Page 1 January 30,  2009 
check to have links open new windows

News Headlines

Elderly Glioblastoma Patients May Be Undertreated
Diet Modification Slows PSA Doubling After Prostate Cancer Treatment
Gene Variants Increase Risk of Alcohol-Related Cancer
Fluorouracil-based Adjuvant Therapy May Cure Colon Cancer
Cured Meats Tied to Childhood Leukemia Risk
Enhanced Patient Intervention Increases Colorectal Screening Compliance
Prostate Cancer May Cause Neglect of Other Illness
Childhood Cancer Survivors Miss Needed Mammograms
Risk Factors Identified to Guide Preventive Mastectomy Decision
High-Dose Epirubicin for Breast Cancer Provides No Overall Benefit
Chemotherapy Enhances Vaccine-Induced Anti-Melanoma Immunity

Cancerpage news is updated daily, Monday through Friday, and on the weekends as warranted.   More than 39 new articles have been added to cancerpage news since the last newsletter.  To see ALL the latest stories, go to the cancerpage.com search page and click on Submit (but leave search field black.) 


Putting TV Medical Drama to the Clinical Test 

Nip/Tuck recently did a commendable job of shedding light on male breast cancer. But in dramatizing the  disease that kills an estimated 450 American men each year, it got some of the medicine wrong. LA Times reporter Marc Siegel decontructed the episode recently, here in his column, The Unreal World.   This is a very interesting read.


Debate over Off-Label Use of Cancer Drugs

Medicare's decision to cover more off-label use of cancer drugs has sparked some serious debate. You can read about it. Shorter verion here. Longer version of the story is available on the NYTimes site  here.  (Access requires a free subscription to the NYT online. You can use the cancerpage login. User: cancerpage  PW: visitor.) Cancerpage ran a news story when Medicare made the announcement January 12th  here .


'Seriously, This is Amazing..

...I'm Brown!!!' --- That's what one of the posters exclaims on a discussion board for people who use an UNAPPROVED product for skin tanning.  An injectible solution -  Melanotan -  is sold on the internet as "synthetic versions of melanocyte stimulating hormone that were created, synthesized and developed at The University of Arizona and the Arizona Cancer Center".  The health agencies of four governments have warned that Melanotan could be dangerous but apparently its popularity is growing. Now a letter in the British Medical Journalreports on two patients who had "rapidly changing moles and a conspicuous tan" when they showed up at the clinic. The moles, all benign, changed after the self-administered injections. One of the moles was "severely dysplastic."  Read letter here. The melanotan discussion board can be found here. FDA Melanotan II warning dated 2007.


Value of Acupuncture in Pain Relief Questioned

Large review of the research concludes the pain relief from acupuncture is small and hard to tease out from the bias of testing. The findings are published in the British Medical Journal: "We found a small analgesic effect of acupuncture that seems to lack clinical relevance and cannot be clearly distinguished from bias. Whether needling at acupuncture points, or at anysite, reduces pain independently of the psychological impactof the treatment ritual is unclear."  Read the report here.


In the Clinic/In the Lab

New research suggests the best time to get chemo is at night, when cancer cells are less able to repair the damage done to their DNA. That's the finding of work by Dr. Aziz Sancar of the University of North Carolina's School of Medicine. He and his team were interested in investigating how doctors could take advantage of the body's circadian rhythm. Read more about their work on how the time of day might affect the potency of chemotherapy here

Men who develop prostate cancer AND carry one of two breast cancer gene mutations (BRCA1 and BRCA2) are more likely to have an aggressive cancer. The presence of the gene mutation could provide the patient and his physician a tool for guiding treatment decisions in an early stage diagnosis, according to researchers at the Albert Einstein College of Medicine of Yeshiva University. 

 


The weekly cancerpage

The weekly cancerpage.com newsletter, Words To Live By, is intended for educational purposes only.
cancerpage.com is a service of The Alere Oncology Program.
Do you have case management services available to you?
Ask your health insurance company about Cancer Case Management.
All rights reserved, cancerpage.com, 2000-2009.

[close window]